KTTA and KTTAW Related Headlines
Go Back- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Pasithea names Kartik Krishnan as chief medical officer
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
- Pasithea Therapeutics receives FDA rare pediatric disease designation for PAS-004
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
- Pasithea Therapeutics provides updated clinical trial timelines
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
- Pasithea advances PAS-004 trial to higher dose after safety review
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Pasithea completes enrollment of first cohort in NF1 drug trial
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
KTTA and KTTAW Related Press Releases
Go Back- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
